🇺🇸 Divalproex (DIV) ER in United States

FDA authorised Divalproex (DIV) ER on 4 August 2000

Marketing authorisations

FDA — authorised 4 August 2000

  • Application: NDA021168
  • Marketing authorisation holder: ABBVIE
  • Local brand name: DEPAKOTE ER
  • Indication: TABLET, EXTENDED RELEASE — ORAL
  • Status: approved

Read official source →

FDA — authorised 20 December 2002

  • Application: NDA020782
  • Marketing authorisation holder: ABBOTT
  • Local brand name: DEPAKOTE ER
  • Indication: Tablet, Extended Release — Oral
  • Status: approved

Read official source →

FDA — authorised 24 March 2008

  • Application: NDA022267
  • Marketing authorisation holder: ABBVIE INC
  • Local brand name: DEPAKOTE ER
  • Indication: TABLET, EXTENDED RELEASE — ORAL
  • Status: approved

Read official source →

Other Neurology / Psychiatry approved in United States

Frequently asked questions

Is Divalproex (DIV) ER approved in United States?

Yes. FDA authorised it on 4 August 2000; FDA authorised it on 20 December 2002; FDA authorised it on 24 March 2008.

Who is the marketing authorisation holder for Divalproex (DIV) ER in United States?

ABBVIE holds the US marketing authorisation.